| 摘要 |
The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and can be used as pharmaceutical active principles for the prophylaxis or treatment of diseases caused by disorders associated with the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme (11-beta-HSD1), such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive changes, Alzheimer's disease, or neurodegeneration. |
